Deintensification of Metformin Therapy in Patients with Low A1C Levels

Introduction to Deintensification

• The American College of Physicians recommends deintensifying pharmacologic therapy when A1C falls below 6.5%, as no trials demonstrate improved clinical outcomes at these levels 1
• Treatment to achieve A1C levels below 6.5% has been associated with increased overall mortality, cardiovascular-related death, and severe hypoglycemic events in major trials like ACCORD 1

Deintensification Strategies

• For a patient with A1C of 4.7%, discontinue metformin entirely if the patient is on monotherapy, as this A1C level indicates excessive glycemic control that provides no benefit and potential harm 1
• Reduce the metformin dose by at least 50% if a more conservative approach is preferred, then recheck A1C in 3 months 1

Evidence Against Treating to Low A1C Levels

• The ACCORD trial, which targeted A1C <6.5% and achieved 6.4%, was discontinued early due to increased mortality 1
• The ADVANCE study showed no statistically significant clinical benefit at an achieved median A1C of 6.4% compared to 7.0%, with more adverse effects in the intensive group 1

Target A1C After Deintensification

• For most adults with type 2 diabetes, the appropriate target is between 7.0-8.0% 1, 2
• If glycemic control can be maintained with lifestyle modifications alone, a target of 6.5% is acceptable, but this should be achieved without pharmacologic therapy 2